Clinical Study
Perspectives of CB1 Antagonist in Treatment of Obesity: Experience of RIO-Asia
Table 3
Change in weight (last observation carried forward) by BMI stratum in intent-to-treat population.
| | BMI: 25 to 27 kg/m2 | BMI: >27 kg/m2 | | Weight (kg) | Placebo () | Rimonabant 20 mg () | Placebo () | Rimonabant 20 mg () |
| | Baseline | | | | | | Mean (SD) | 67.42 (6.21) | 69.28 (7.45) | 86.19 (16.22) | 84.23 (14.81) | | Month 9 (LOCF) | | | | | | Mean (SD) | 66.06 (6.93) | 65.47 (8.51) | 84.20 (16.50) | 79.14 (15.33) | | Change from baseline | | | | | | Mean (SD) | −1.37 (2.95) | −3.81 (3.59) | −1.99 (4.55) | −5.09 (5.37) | | LS Mean (SEM) | −1.35 (0.384) | −3.84 (0.387) | −2.02 (0.315) | −5.18 (0.316) | | LS Mean Difference (SEM) | — | −2.49 (0.548) | — | −3.16 (0.446) | | 95%CI | — | (−3.570 to −1.403) | — | (−4.034 to −2.283) | | P value | — | <.0001 | — | <.0001 | | Percent change from baseline | | | | | | Mean (SD) | −2.05 (4.58) | −5.61 (5.33) | −2.31 (4.94) | −6.11 (6.22) |
|
|
BMI: body mass index. CI: confidence interval. LS: least square. LOCF: last observation carried forward.
|
